DEUS MEDICAL - MOD GRF 1-29 - 2 MG/VIAL
DEUS MEDICAL - MOD GRF 1-29 - 2 MG/VIALDEUS MEDICAL - MOD GRF 1-29 - 2 MG/VIAL

DEUS MEDICAL – MOD GRF 1-29 – 2 MG/VIAL

27.00

Overview

MOD GRF 1-29 is a man-made peptide that is an analog of growth hormone releasing hormone (GHRH). It is used to treat growth hormone deficiency or growth failure. It is also used to treat dwarfism and prevent weight loss.

MOD GRF 1-29 Mechanism of Action

MOD GRF 1-29 acts on the GHRH receptor to stimulate growth hormone release. It is a 29 amino acid peptide, which is less than the natural GHRH (44 amino acids). On its own, GRF 1-29 has a half-life of about 10 minutes. However, when it is modified to MOD GRF 1-29, the half-life is increased to about 30 minutes.

MOD GRF 1-29 Side Effects

Flushing, pain at the injection site, nausea and vomiting, headaches, allergic reaction, and difficulty breathing.

MOD GRF 1-29 Interactions

COX inhibitors, glucocorticoids, atropine, levodopa.

 

http://advarpharma.eu

Add to wishlist Product added! The product is already in your wishlist!

Description

Overview

MOD GRF 1-29 is a man-made peptide that is an analog of growth hormone releasing hormone (GHRH). It is used to treat growth hormone deficiency or growth failure. It is also used to treat dwarfism and prevent weight loss.

MOD GRF 1-29 Mechanism of Action

MOD GRF 1-29 acts on the GHRH receptor to stimulate growth hormone release. It is a 29 amino acid peptide, which is less than the natural GHRH (44 amino acids). On its own, GRF 1-29 has a half-life of about 10 minutes. However, when it is modified to MOD GRF 1-29, the half-life is increased to about 30 minutes.

MOD GRF 1-29 Side Effects

Flushing, pain at the injection site, nausea and vomiting, headaches, allergic reaction, and difficulty breathing.

MOD GRF 1-29 Interactions

COX inhibitors, glucocorticoids, atropine, levodopa.

 

http://advarpharma.eu

Reviews

There are no reviews yet.

Be the first to review “DEUS MEDICAL – MOD GRF 1-29 – 2 MG/VIAL”

Your email address will not be published. Required fields are marked *